- Conditions
- Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
- Interventions
- Daromun, Surgery, Adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2031
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced Basal Cell Carcinoma
- Interventions
- L19IL2/L19TNF
- Drug
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- L19TNF, DOXORUBICIN
- Drug
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Leiomyosarcoma
- Interventions
- Doxorubicin, L19TNF plus doxorubicin
- Drug · Combination Product
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 16 Years to 100 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 5 more
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDA®
- Drug
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Hartford, Connecticut • New York, New York
- Conditions
- Glioblastoma
- Interventions
- L19TNF, Lomustine
- Drug
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 4 more
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma
- Interventions
- L19IL2/L19TNF
- Drug
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 6
- States / cities
- Orange, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Locally Advanced Basal Cell Carcinoma
- Interventions
- L19IL2, L19TNF, L19IL2/L19TNF
- Drug
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Atlanta, Georgia • Durham, North Carolina + 3 more